$Novo Nordisk AS(NVO.US)The highlight is the oral drug, with 200k prescriptions already that week and a cumulative 2 million, more than ten times that of Eli Lilly. Also, the oral drug will launch in Europe in the second half of the year, so it can be held for the long term.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments